           |
Press Releases 2007 December 10, 2007 Fake Drugs and XStream Systems' Solution Featured on FOX News November 30, 2007 The Need to Protect America's Pharmaceutical Supply November 13, 2007 XStream Systems Add More Pharmaceutical Experience October 22, 2007 Former Pharmaceutical Executive Joins XStream Systems September 12, 2007 Identifying Imported Counterfeit Drugs June 14, 2007 Phase II of Independent Laboratory Evaluations January 30, 2007 XStream Systems Begins National Ad Campaign
2006 October 3, 2006 Independent Testing Results Prove XT250's Greater Than 99% Accuracy Rate June 30, 2006 Kimball Electronics Forms Strategic Partnership with XStream Systems
Full
Press Releases 2007 December 10, 2007 Fake Drugs and XStream Systems' Solution Featured on Fox News The number of counterfeit medications in America and a possible solution to protect consumers was broadcast across the nation today. FOX News Channel aired a feature on XStream Systems and the unit which can authenticate questionable medications. The story discussed the significant issues surrounding counterfeit medications within the domestic supply chain and the use of technology, such as EDXRD and the XT250 System as a solution. With this unit, manufacturers, distributors, and dispensers can verify the contents of pharmaceutical containers without breaking their seal. In addition the airing captured the evolution of the XT250 System over the years. The FOX News Channel correspondent on the case was Orlando Salinas. Also featured was Alan Clock, Senior Vice President of Sales and Marketing at XStream Systems. “We were contacted by FOX about a possible visit to our headquarters and our expertise regarding the scope of counterfeiting within the US,” stated Clock. “Ultimately, the news footage proved to be a great way to present our solution to a large audience.” In his report, Salinas cited the WHO (World Health Organization) regarding the increasing scope of counterfeit medications and ICE (Immigration Customs Enforcement). This year, ICE has investigated over 200 cases of smuggling of prescription medications and over 650 foreign internet sites that sell into the United States.
To view the FOX News Channel story and other videos, click here to get to "secure pharma chain."
November 30, 2007 The Need to Protect America's Pharmaceutical Supply
As America’s consumption of pharmaceuticals increases,
so must methods to thwart the counterfeit drug market. In 2006, prescription sales in the US
pharmaceutical market increased by 8.3% and in 2007, similar growth is anticipated. Global industry experts agree that on average 10% of the world’s
drug supply is considered counterfeit, adulterated or otherwise fraudulent. With Americans purchasing
44% of all pharmaceuticals sold worldwide last year, if only 1% of the US drug supply was tainted it would
equal 34.2 million prescriptions that are potentially life threatening. This equates to approximately one
counterfeit prescription for every nine American citizens in 2006 alone. The World Health Organization’s Anti-Counterfeiting Taskforce has
stated “technologies are particularly important for product authentication.” To fill a need for a high-tech
solution, scientists and engineers at a Florida-based company have developed a unit which can help maintain
the integrity of the pharmaceutical supply chain. The XT250TM System by XStream Systems, Inc. is the first
of its kind and can verify the contents of a manufacturer’s original unit of sale, without breaking the
seal or opening the package. When placed at distribution checkpoints or warehouse facilities, the unit
is able to determine fraudulent medications from legitimate inventory, thus protecting the consumer. A study by the Center for Medicine in the Public Interest cited by the
WHO estimates the number of counterfeits will climb to be a $75 billion industry by the year 2010,
representing a 92% increase from 2005. John Lundquist, XStream Systems’ VP of Business Development states
“As the threat of consumers being harmed by counterfeit drugs grows, we need to increase the number of
safeguards throughout the pharmaceutical supply chain. The XT250 System is the most robust technology of
a new generation of necessary anti-counterfeiting solutions.”
November 13, 2007 XStream Systems Add More Pharmaceutical Experience
XStream Systems, Inc. announced the addition of another key
individual assisting the rollout of their pharmaceutical authentication technology. John Lundquist has
joined the company as Vice President of Sales and Business Development. Mr. Lundquist will report to
Alan Clock, the Senior Vice President of Sales and Marketing. Mr. Lundquist will be responsible for large enterprise sales and
business development efforts for XStream Systems. “John’s experience is the perfect fit for XStream Systems,”
stated Clock. “We feel that he will be able to place our product and its technology further into the
healthcare supply chain.” Mr. Lundquist joins XStream Systems with a strong track record of
experience in pharmaceutical sales, business development, operations, supply chain and group purchasing
management. Prior to joining the XStream Systems team, Mr. Lundquist directed a national
Specialty/Biotech Distribution enterprise. Mr. Lundquist is an expert strategist and negotiator known
for pioneering new business tactics and partnerships aimed at pharmaceutical supply chain solutions.
He has also held executive positions with Managed Healthcare Associates, AmerisourceBergen and
Fujisawa USA.
October 22, 2007 Former Pharmaceutical Executive Joins XStream Systems
Brian Mayo, President of XStream Systems, Inc., a Florida based
material identification company, announced the addition of Alan Clock as Senior Vice President of Sales
and Marketing. In the position of Senior Vice President of Sales and Marketing,
Mr. Clock will be responsible for directing all sales and marketing efforts for XStream Systems. “Alan brings us a great amount of experience and expertise in
the pharmaceutical and healthcare provider markets,” stated Mayo. “We feel that our product and its
technology are the perfect fit for the healthcare supply chain and the many issues that they have as
they source products globally. Alan gives us the contacts and credibility to properly provide our
solution to these markets and others.” Mr. Clock joins XStream Systems with wealth of experience in
sales and sales management primarily dealing with healthcare services, systems and solutions. He has
held senior sales executive and national account roles for industry leaders; AmerisourceBergen,
McKesson, Cardinal Health and ActiveHealth Management. “I am excited about this ground breaking technology and
being at the forefront of providing solutions to an uncertain global supply chain,” stated Clock.
“XStream’s first generation product, the XT250™ System is perfectly suited to help authenticate
materials at vulnerable spots along the supply chain network.”
September 12, 2007 Identifying Imported Counterfeit Drugs
A Florida-based company has begun selling a piece of equipment which can detect
counterfeit drugs in the U.S. pharmaceutical supply chain. XStream Systems, Inc. developed a unit to identify dangerous
pharmaceuticals in circulation to protect the public by authenticating these medications before they reach the
consumer. The threat of Americans swallowing counterfeit medications is increasing each
year. The World Health Organization has stated trade in fake medicines is more prevalent in countries with weak drug
regulation and enforcement, scarcity or erratic supply of basic medicines, unregulated markets and unaffordable prices.
But as counterfeiting becomes more sophisticated, these products are increasingly present even in better controlled
markets. Daniel M. Durand, VP of Sales for XStream Systems says “Some undeveloped nations see regions where circulated
counterfeit pharmaceutical rates soar into the high 30th percentile – to protect the public, we need to take action
and make sure medications are validated before consumption.” XStream Systems’ unit authenticates a drug while still in its sealed container.
The “fingerprint” of each drug is completely unique, so questionable medications can be compared to the actual drug’s
fingerprint. To do this, an operator places a bottle into the unit and presses the “start” button on a touch screen.
The molecular crystal structure of the drug is then examined and compared against stored data to receive a “passed”
or “failed” message To date, U.S. Immigration and Customs Enforcement has initiated over 178
criminal investigations of pharmaceutical smuggling. These investigations have targeted over 650 websites and
millions of dosage units of counterfeit, adulterated, misbranded and unapproved pharmaceuticals – all available
to American consumers. XStream Systems’ unit is the first of its kind. XStream Systems, Inc. XStream Systems produces next-generation equipment for material identification.
Their patented systems are based on Energy-Dispersive X-Ray Diffraction (EDXRD) technology. The company’s XT250™ System
enables testing of powders, pills AND entire sealed bottles. The equipment’s superior sample penetration allows the
identification of contents inside opaque plastic, cardboard and even metal packaging.
June 14, 2007 Phase II of Independent Laboratory Evaluations
The XStream Systems XT250 Material Identification System has completed phase II of
independent testing. Once again, the results have proven the accuracy of the unit. This particular round of testing was
completed using some prescription medications prone to counterfeiting: XT250 (Field Test Plan) Independent Lab Test Plan – Phase II This report is being submitted to satisfy a contractual agreement and contains
the results of an independent evaluation of a technology developed by XStream Systems, Inc. (Vero Beach, FL). The evaluation was performed by the Florida Technical Division of Midwest
Research Institute (Palm Bay, FL). The purpose of this independent evaluation was to test the sensitivity and specificity
of the XStream Systems, Inc. XT250 Material Recognition System Engine in identifying known prescription drugs based on
simple pass/fail criteria. Combiviv 150/300, Epivir 150, Viagra 100, Truvada 200/300, and Hyzaar 50/12.5 were provided
by XStream Systems, Inc and pills were dispensed into sample vials. An MRI scientist performed all testing at the XStream Systems, Inc.
facility. The instrument was programmed to identify all 5 of the test samples and testing was conducted over a six day period. The
evaluation consisted of 50 independent runs performed on each of the five samples used in this analysis with the instrument programmed
for positive identification and 50 independent runs on each of the five samples with the instrument programmed for misidentification
for a total of 500 measurements. Equal volumes (18.5 cm3) of each sample were exposed for 5 minutes. The results showed that the XT250 accurately identified 97.2% of the positive samples (N=250).
The instrument accurately identified 249 out of 250 negative samples, demonstrating a specificity of 99.6%. The overall efficiency
(accuracy) of the diagnostic test, defined as the percentage of samples correctly classified, was 98.4%; 492 out of the 500 samples.
The calculated probability of the XT250 correctly classifying these drugs was 0.986. Statistical analysis by a Chi Squared Test demonstrated there was no statistically significant difference between the observed
results and the expected results, X2YATES (1, N=500) = 0.100, p=0.752. These test results indicate that the XStream Systems Inc.
XT250 Material Recognition System Engine accurately classified 492 out of 500 drug samples in this evaluation.
January 30, 2007 XStream Systems Begins National Ad Campaign
Vero Beach, FL— Businesses across the nation have begun reading about a company offering a
high-tech solution to a growing concern: counterfeit medicine. A national business to business ad campaign has begun introducing the
pharmaceutical manufacturing and distribution industries to XStream Systems, Inc. and their next-generation technology. Using X-ray based detection equipment, the company’s XT250 System can verify medications by
looking at their molecular structure. “Each medication has a unique molecular fingerprint that we can scan and identify a drug as
being real or counterfeit” says Daniel M. Durand, VP of XStream Systems. “Counterfeit pharmaceuticals are a real threat to the
industry and the public. We are reaching out across the nation to let the pharmaceutical industry know they have another option in
the fight against these counterfeits with an easy-to-use system that can detect phony medications with greater than 99% accuracy. ” XStream Systems is headquartered in Vero Beach, FL and in the midst of tremendous growth.
Brian Mayo, CEO of the company described the activity within the facility at a “fever pitch”. Postcards and direct mail pieces
are being sent out over the course of four weeks, seeding key players in the industry with news of much needed technology coming
their way. Advertisements for the XStream Systems’ XT250 Material Identification System are appearing in this month’s “Healthcare
Distributor” magazine. Even the XStream Systems’ national trade show circuit is going into high gear, with the company appearing
at eight shows in the first half of 2007 alone. “There is no doubt the pharmaceutical industry is an enormous target market” says
Michael DeBoer of XStream Systems, “so we are being very selective on who and how we hit first.” DeBoer adds, “Our equipment
can be used in many different industries, but this one seems to fit real well. The pharmaceutical community is trying to figure
out how to fight counterfeits as we are letting them know we are here to help- we have begun connecting”. Headquartered in Vero Beach, XStream Systems produces next-generation equipment for
material identification. Their patented systems are based on energy-dispersive X-ray diffraction (EDXRD), a highly sensitive
and accurate technology previously available only in expensive, high-end systems used by major laboratories. They bring on-site,
real-time material identification within the reach of nearly any organization. 2006
October 3, 2006 Independent Testing Results Prove XT250's
Greater Than 99% Accuracy Rate
The XStream Systems XT250 has recently completed independent testing. The results from the process prove
a 99.4% accuracy rate when identifying pharmaceuticals. This is a phenomenal achievement for a material identification system, and XStream Systems is proud to post the following summary
XT250 Independent Laboratory Evaluation This report is being submitted to satisfy a contractual agreement and contains the results
of an independent evaluation of a technology developed by XStream Systems, Inc. (Vero
Beach, FL). The evaluation was performed by the Florida Technical Division of the
Midwest Research Institute (MRI, Palm Bay, FL).
The purpose of this initial evaluation
was to test the sensitivity and specificity of the XStream Systems, Inc. XT250 Material
Recognition System Engine in identifying known over the counter (OTC)
pharmaceuticals using a simple pass/fail criteria
Tagamet HB 200, Aleve, Dramamine,
Motrin IB, Nuprin, Zantac 150, and BC Powder were purchased by MRI staff.
Expiration dates and lot numbers were recorded and pills were dispensed into sample
vials. Sample materials were kept in the possession of MRI for the duration of the
evaluation. An MRI scientist performed all testing at the XStream Systems, Inc. facility
following a 10 minute training session provided by XStream Systems, Inc. technical staff.
The instrument was programmed to identify three of the eight test samples, and testing
was conducted over a three day period. The evaluation consisted of 20 independent runs
performed on each of the eight samples used in this analysis; totaling 160 measurements.
Equal volumes (18.5 cm3) of each sample were exposed for 10 minutes.
The results
showed that the XT250 accurately identified 98% of the samples (n=60). Only one
compound was misidentified in one out of 20 replicates, Dramamine, and was
independent of lot number or expiration date. The instrument accurately identified all
negative samples (n= 100), demonstrating a specificity of 100%. The overall efficiency
(accuracy) of the diagnostic test, defined as the percentage of samples correctly
classified, was 99.38%; 159 out of the 160 samples. The calculated probability of the
XT250 correctly classifying these drugs was 0.98.
Statistical analysis by a Chi Squared
Test demonstrated no statistically significant difference between the observed results and
the expected results, X2Yates = (1, N=160) = 0.0067, p=0.94 These test results indicate
that the XStream Systems Inc. XT250 Material Recognition System Engine accurately
classified 159 out of 160 drug samples in this initial evaluation.
June 30, 2006 Kimball Electronics Forms Strategic Partnership with XStream Systems
Kimball Electronics Group, Inc., (www.kegroup.com) through its related subsidiaries, announced today that the company has entered into an agreement with XStream Systems, Inc. to manufacture their XT250 Material Identification System. Kimball Electronics Group, Inc., a subsidiary of Kimball International, Inc. (NASDAQ:KBALB), is a global contract electronics manufacturing services (EMS) company that specializes in durable electronics with applications in the public safety, automotive, medical, and industrial controls industries. XStream Systems, Inc. is a company that ds and sesignells next-generation material identification equipment for verification and detection of substances as wide-ranging as illicit drugs, pharmaceuticals, chemicals, and food products. Don Charron, President, Kimball Electronics Group, stated, "We are excited about being the strategic manufacturing partner for XStream, and we believe that their newly developed and patented Energy-Dispersive X-Ray Diffraction (EDXRD) technology will quickly establish them as a market leader." Brian Mayo, President and CEO, XStream Systems, said, "Kimball's commitment to be both a business partner as well as a supplier is very important to XStream and we look forward to a long lasting relationship." Jim Thyen, President and CEO of Kimball International, Inc., said, "XStream Systems, Inc. has developed a unique, innovative product providing a valuable service for the public safety in our communities. We are honored to be chosen as the preferred supplier and to have earned the opportunity this brings for growth and diversification." Under the terms of the agreement, Kimball Electronics will assemble, test, service, and repair the XT250 x-ray system in their Jasper, Indiana facility, with first production units shipping later this year.
About Kimball Electronics: Kimball Electronics Group is well recognized for its excellent quality, reliability and innovative service. The September 2005 issue of "Electronic Business" magazine ranked Kimball Electronics as #26among the global Top 100 Contract Manufacturers. In June 2005,"Electronics Supply & Manufacturing" magazine rated Kimball Electronics #20 among the Top 50 Electronics Manufacturing Services Companies. Kimball Electronics Group has manufacturing operations in the U.S., Mexico, Thailand, Poland, Wales, Ireland, and a soon to be completed new facility in China. To learn more about Kimball Electronics, visit the Company's website on the Internet at: www.kegroup.com
About XStream Systems, Inc.: XStream Systems, Inc., founded in 2004, is headquartered in Vero Beach, Florida. The company's products are based on a technology called Energy-Dispersive X-Ray Diffraction (EDXRD), that can be used to quickly identify unknown substances based on their crystalline structure. This highly sensitive technology was previously available only in expensive, large-scale systems used at major research centers. The company plans to bring material identification capabilities within reach of nearly any organization, with easy-to-use, affordable products.
About Kimball International: Recognized with a reputation for excellence, Kimball International is committed to a high performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball employees know they are part of a corporate culture that builds success for customers while enabling employees to share in the company's success through personal, professional and financial growth. Kimball International, Inc. (NASDAQ:KBALB) provides a variety of products from its two business segments: the Furniture and Cabinets segment and the Electronic Contract Assemblies segment. The Electronic Contract Assemblies segment provides engineering and manufacturing services which utilize common production and support capabilities to a variety of industries globally. The Furniture and Cabinets segment provides furniture for the office and hospitality industries, sold under the Company's family of brand names. The Furniture and Cabinets segment also provides engineering and manufacturing services which utilize common production and support capabilities on a contract basis to customers primarily in the residential furniture and cabinets industry. To learn more about Kimball International, Inc., visit the Company's website on the Internet at: http://www.kimball.com/ "Kimball International ... We Build Success!"
|
Archived Press Releases
|
